Bilayer Tablet Hardness and Release Profile Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bilayer tablet formulations of metformin and dapagliflozin face challenges such as delayed onset of action, stability issues, and content uniformity problems due to the hygroscopic nature of dapagliflozin and the high solubility of metformin, leading to inefficient release profiles and stability concerns.
Innovation Solution
A bilayer tablet composition with a hardness of more than 253 N, comprising an extended-release layer of metformin and an immediate-release layer of dapagliflozin, utilizing specific excipients such as microcrystalline cellulose, hydroxypropylmethylcellulose, and croscarmellose sodium to achieve stable and controlled release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release layer is used for dapagliflozin, then rapid onset of action is achieved, but content uniformity problems occur due to hygroscopic nature
Solution Approach 1:
The tablet is divided into two distinct layers: an immediate-release layer containing dapagliflozin for rapid onset, and an extended-release layer containing metformin for sustained effect. This segmentation allows each layer to be optimized independently, with the immediate-release layer formulated to achieve rapid dissolution while maintaining content uniformity through controlled granulation and compression parameters.
Solution Approach 2:
A membrane coating is applied to the immediate-release layer containing dapagliflozin to act as a barrier against moisture absorption. This intermediary layer prevents the hygroscopic dapagliflozin from directly interacting with environmental moisture, thereby maintaining content uniformity while preserving the rapid onset of action through controlled porosity of the coating.
2Duration of action of moving object
If extended release formulation is used for metformin, then prolonged duration of action is achieved, but delayed onset of action occurs
Solution Approach 1:
The bilayer tablet structure separates metformin into an extended-release layer that provides prolonged duration of action, while the adjacent immediate-release layer of dapagliflozin provides rapid onset. This segmentation allows the metformin layer to be optimized for sustained release without compromising the overall onset time of the combination product.
Solution Approach 2:
The patent combines immediate-release dapagliflozin and extended-release metformin in a single bilayer tablet, merging two different release profiles into one dosage form. This combination allows the rapid-acting dapagliflozin to provide immediate glucose control while the extended-release metformin sustains the effect throughout the day, achieving both rapid onset and prolonged duration simultaneously.
3Productivity
If bilayer tablet structure is used, then improved release profile is achieved, but tablet hardness decreases
Solution Approach 1:
The patent optimizes compression parameters including pressure, time, and temperature to achieve the required tablet hardness for bilayer structures. By carefully controlling these parameters, the formulation maintains adequate mechanical strength while preserving the differentiated release profiles of the two layers through appropriate pore structure and density control.
Solution Approach 2:
The bilayer tablet uses composite material formulations in each layer, with specific excipients and binders selected to provide both structural integrity and controlled release properties. The immediate-release layer uses materials that facilitate rapid dissolution, while the extended-release layer uses matrix-forming materials, and both are bonded together to create a mechanically sound single tablet.
Data Source
AI summary
The invention relates to a bilayer tablet comprising metformin in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph thereof and dapagliflozin in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph thereof, and at least one pharmaceutically acceptable excipient, wherein the bilayer tablet has a hardness of more than 253 N.